Hubei Jumpcan Pharmaceutical (600566) Q3 2025 earnings summary

Executive summary

• Revenue for the first nine months of 2025 was RMB 3.93 billion, down 32.27% year-over-year, mainly due to decreased demand in the terminal market and lower sales of key products.

• Net profit attributable to shareholders for the same period was RMB 1.02 billion, a 46.27% decrease year-over-year.

• Cash flow from operating activities dropped 59.56% year-over-year to RMB 703.5 million.

Financial highlights

• Q3 revenue was RMB 1.18 billion, down 33.17% compared to the same quarter last year.

• Q3 net profit attributable to shareholders was RMB 298.1 million, a 47.19% decrease year-over-year.

• Basic and diluted EPS for the first nine months were both RMB 1.11, down 46.38% year-over-year.

• Total assets at quarter-end were RMB 16.53 billion, down 10.43% from the previous year-end.

• Shareholders’ equity was RMB 13.83 billion, a 5.93% decrease from year-end 2024.

Key financial ratios and metrics

• Gross margin for the first nine months was approximately 76.3%.

• Weighted average ROE for the first nine months was 7.12%, down 6.57 percentage points year-over-year.

• Operating margin and net margin both declined significantly due to lower sales and profit.